PI-88

DRUG8 trials

Sponsors

Cellxpert Biotechnology Corp., Progen Pharmaceuticals

Conditions

CancerCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungHepatocellular CarcinomaHepatomaLiver CancerLung CancerMelanoma

Phase 1

Study of PI-88 in Patients With Advanced Melanoma

CompletedNCT00068172

Cellxpert Biotechnology Corp.Melanoma

Start: 2001-07-31End: 2007-06-30Target: 88Updated: 2022-06-27

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

CompletedNCT00073892

Cellxpert Biotechnology Corp.Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific

Start: 2004-01-31End: 2005-11-30Updated: 2022-06-27

Phase 2

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

CompletedNCT00097851

Cellxpert Biotechnology Corp.Carcinoma, Non-Small-Cell Lung

Start: 2004-02-29End: 2006-07-31Target: 100Updated: 2022-06-27

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

CompletedNCT00103389

Cellxpert Biotechnology Corp.Lung Cancer

Start: 2004-02-29End: 2007-05-31Updated: 2022-06-27

PI-88 in Hepatocellular Carcinoma After Hepatectomy

CompletedNCT00247728

Cellxpert Biotechnology Corp.Carcinoma, Hepatocellular

Start: 2004-06-30End: 2008-06-30Updated: 2022-06-23

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

CompletedNCT00268593

Progen PharmaceuticalsProstate Cancer

Start: 2005-08-31End: 2008-02-29Updated: 2011-06-15

Phase 3

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

TerminatedNCT00568308

Progen PharmaceuticalsCancer, Hepatocellular Carcinoma, Hepatoma +2

Start: 2007-12-31End: 2008-07-31Target: 600Updated: 2011-06-15

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

TerminatedNCT01402908

Cellxpert Biotechnology Corp.Cancer, Hepatocellular Carcinoma, Liver Cancer

Start: 2011-08-31End: 2015-01-31Updated: 2022-06-23